{"id":352757,"date":"2026-11-18T15:06:35","date_gmt":"2026-11-18T09:36:35","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=352757"},"modified":"2026-11-18T15:06:35","modified_gmt":"2026-11-18T09:36:35","slug":"dr-agarwals-health-care-analyst-review","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/dr-agarwals-health-care-analyst-review\/","title":{"rendered":"Dr Agarwal&#8217;s Analyst Review 2027: Record Revenue and 324 Centres as Motilal Oswal Eyes \u20b9620"},"content":{"rendered":"<div style=\"background:#E8F1FF;border-left:5px solid #1565C0;padding:16px 20px;margin:0 0 20px 0;border-radius:6px;\">\n<p><strong>Dr. Agarwal&#8217;s Health Care Stock Snapshot (17 Nov 2026 close)<\/strong><\/p>\n<ul>\n<li><strong>Current Market Price (CMP):<\/strong> \u20b9539.95<\/li>\n<li><strong>52-Week High \/ Low:<\/strong> \u20b9571.90 \/ \u20b9401.00<\/li>\n<li><strong>Market Capitalisation:<\/strong> \u20b917,114 crore<\/li>\n<li><strong>P\/E Ratio vs Industry P\/E:<\/strong> 83.3 vs 63.9<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Revenue:<\/strong> \u20b9655 crore<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Net Profit:<\/strong> \u20b957 crore<\/li>\n<\/ul>\n<\/div>\n<div style=\"background:#F0F9FF;border-left:5px solid #2E7D32;padding:16px 20px;margin:0 0 20px 0;\">\n<p><strong>Quick Answer:<\/strong> The <strong>Dr Agarwal&#8217;s analyst review 2027<\/strong> has one verified target: Motilal Oswal&#8217;s Buy with \u20b9620 from August 2026, about 15% above the \u20b9539.95 close. Q2 FY27 revenue from operations rose about 31.4% to a record \u20b9655 crore and net profit rose to about \u20b957 crore from \u20b936.49 crore. The chain added 21 facilities in the quarter to reach 324. The stock trades near 83 times trailing earnings against an industry P\/E of about 64, so the <strong>Dr Agarwal&#8217;s share price target 2027<\/strong> depends on new centres turning profitable quickly.<\/p>\n<\/div>\n<p>The <strong>Dr Agarwal&#8217;s analyst review 2027<\/strong> covers India&#8217;s largest eye care hospital chain, which runs cataract, refractive and retina surgery centres across India and in parts of Africa. Investors searching for a <strong>Dr Agarwal&#8217;s share price target 2027<\/strong> will find one named <strong>brokerage<\/strong> figure that still sits above the current price.<\/p>\n<p><a href=\"https:\/\/univest.in\/stocks\/agarwaleye\/dr-agarwals-health-care-l-share-price-today\">Dr. Agarwal&#8217;s Health Care<\/a> closed at \u20b9539.95 on 17 November 2026. That is about 6% below its 52-week high of \u20b9571.90 and about 35% above its low of \u20b9401. This Dr Agarwal&#8217;s analyst review 2027 sets out the <strong>brokerage<\/strong> view, the September quarter and the factors that will shape the <strong>Dr Agarwal&#8217;s stock outlook 2027<\/strong>.<\/p>\n<p><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=dr-agarwals-health-care-analyst-review\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/dr-agarwals-health-care-analyst-review\/#What_Brokerages_Say_in_the_Dr_Agarwals_Analyst_Review_2027\" title=\"What Brokerages Say in the Dr Agarwal&#8217;s Analyst Review 2027\">What Brokerages Say in the Dr Agarwal&#8217;s Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/dr-agarwals-health-care-analyst-review\/#Q2_FY27_Results_in_the_Dr_Agarwals_Analyst_Review_2027\" title=\"Q2 FY27 Results in the Dr Agarwal&#8217;s Analyst Review 2027\">Q2 FY27 Results in the Dr Agarwal&#8217;s Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/dr-agarwals-health-care-analyst-review\/#How_Dr_Agarwals_Health_Care_Makes_Money\" title=\"How Dr. Agarwal&#8217;s Health Care Makes Money\">How Dr. Agarwal&#8217;s Health Care Makes Money<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/dr-agarwals-health-care-analyst-review\/#Growth_Triggers_in_the_Dr_Agarwals_Analyst_Review_2027\" title=\"Growth Triggers in the Dr Agarwal&#8217;s Analyst Review 2027\">Growth Triggers in the Dr Agarwal&#8217;s Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/dr-agarwals-health-care-analyst-review\/#Key_Risks_in_the_Dr_Agarwals_Analyst_Review_2027\" title=\"Key Risks in the Dr Agarwal&#8217;s Analyst Review 2027\">Key Risks in the Dr Agarwal&#8217;s Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/dr-agarwals-health-care-analyst-review\/#Dr_Agarwals_Analyst_Review_2027_Stock_at_a_Glance\" title=\"Dr Agarwal&#8217;s Analyst Review 2027: Stock at a Glance\">Dr Agarwal&#8217;s Analyst Review 2027: Stock at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/dr-agarwals-health-care-analyst-review\/#Shareholding_Trend\" title=\"Shareholding Trend\">Shareholding Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/dr-agarwals-health-care-analyst-review\/#What_to_Watch_After_the_Dr_Agarwals_Analyst_Review_2027\" title=\"What to Watch After the Dr Agarwal&#8217;s Analyst Review 2027\">What to Watch After the Dr Agarwal&#8217;s Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/dr-agarwals-health-care-analyst-review\/#Final_Word_on_the_Dr_Agarwals_Analyst_Review_2027\" title=\"Final Word on the Dr Agarwal&#8217;s Analyst Review 2027\">Final Word on the Dr Agarwal&#8217;s Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/dr-agarwals-health-care-analyst-review\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/dr-agarwals-health-care-analyst-review\/#What_does_the_Dr_Agarwals_analyst_review_2027_show\" title=\"What does the Dr Agarwal&#8217;s analyst review 2027 show?\">What does the Dr Agarwal&#8217;s analyst review 2027 show?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/dr-agarwals-health-care-analyst-review\/#What_is_the_Dr_Agarwals_share_price_target_2027_from_brokerages\" title=\"What is the Dr Agarwal&#8217;s share price target 2027 from brokerages?\">What is the Dr Agarwal&#8217;s share price target 2027 from brokerages?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/dr-agarwals-health-care-analyst-review\/#How_did_Dr_Agarwals_Health_Care_perform_in_H1_FY27\" title=\"How did Dr. Agarwal&#8217;s Health Care perform in H1 FY27?\">How did Dr. Agarwal&#8217;s Health Care perform in H1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/dr-agarwals-health-care-analyst-review\/#How_does_Dr_Agarwals_Health_Care_make_money\" title=\"How does Dr. Agarwal&#8217;s Health Care make money?\">How does Dr. Agarwal&#8217;s Health Care make money?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/dr-agarwals-health-care-analyst-review\/#Is_the_stock_expensive_based_on_the_Dr_Agarwals_analyst_review_2027\" title=\"Is the stock expensive based on the Dr Agarwal&#8217;s analyst review 2027?\">Is the stock expensive based on the Dr Agarwal&#8217;s analyst review 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/dr-agarwals-health-care-analyst-review\/#What_risks_does_the_Dr_Agarwals_analyst_review_2027_highlight\" title=\"What risks does the Dr Agarwal&#8217;s analyst review 2027 highlight?\">What risks does the Dr Agarwal&#8217;s analyst review 2027 highlight?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/dr-agarwals-health-care-analyst-review\/#What_should_investors_track_after_the_Dr_Agarwals_analyst_review_2027\" title=\"What should investors track after the Dr Agarwal&#8217;s analyst review 2027?\">What should investors track after the Dr Agarwal&#8217;s analyst review 2027?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Brokerages_Say_in_the_Dr_Agarwals_Analyst_Review_2027\"><\/span><strong>What Brokerages Say in the Dr Agarwal&#8217;s Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Brokerage<\/th>\n<th>Rating<\/th>\n<th>Target Price<\/th>\n<th>Date<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Motilal Oswal<\/td>\n<td>Buy<\/td>\n<td>\u20b9620<\/td>\n<td>August 2026, after Q1 FY27<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Motilal Oswal set its \u20b9620 target after the June quarter results. The <strong>brokerage<\/strong> case rests on steady same-centre growth, a rising share of premium surgeries and a fast pace of network additions. The target implies about 15% upside from the 17 November close.<\/p>\n<p>The September quarter supported that view with record revenue and higher profit. The Dr Agarwal&#8217;s analyst review 2027 will be tested on whether that pace holds while dozens of new centres ramp up at the same time.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY27_Results_in_the_Dr_Agarwals_Analyst_Review_2027\"><\/span><strong>Q2 FY27 Results in the Dr Agarwal&#8217;s Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Total Income<\/th>\n<th>EBITDA<\/th>\n<th>Net Profit<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Sep 2026 (Q2 FY27)<\/td>\n<td>\u20b9665.21 crore<\/td>\n<td>\u20b9185.56 crore<\/td>\n<td>\u20b956.85 crore<\/td>\n<\/tr>\n<tr>\n<td>Jun 2026 (Q1 FY27)<\/td>\n<td>\u20b9620.43 crore<\/td>\n<td>\u20b9176.82 crore<\/td>\n<td>\u20b955.02 crore<\/td>\n<\/tr>\n<tr>\n<td>Mar 2026 (Q4 FY26)<\/td>\n<td>\u20b9576.69 crore<\/td>\n<td>\u20b9174.05 crore<\/td>\n<td>\u20b949.96 crore<\/td>\n<\/tr>\n<tr>\n<td>Dec 2025 (Q3 FY26)<\/td>\n<td>\u20b9540.40 crore<\/td>\n<td>\u20b9154.64 crore<\/td>\n<td>\u20b943.63 crore<\/td>\n<\/tr>\n<tr>\n<td>Sep 2025 (Q2 FY26)<\/td>\n<td>\u20b9506.62 crore<\/td>\n<td>\u20b9144.07 crore<\/td>\n<td>\u20b936.49 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Revenue from operations rose about 31.4% to \u20b9655 crore from \u20b9499 crore, the highest in the company&#8217;s history. <strong>EBITDA<\/strong> rose about 29% to \u20b9185.56 crore. <strong>Net profit<\/strong> climbed about 56% to \u20b956.85 crore, and profit has now risen for five straight quarters.<\/p>\n<p>For the first half of FY27, revenue rose about 28.7% to \u20b91,269.48 crore and profit rose about 50.1% to \u20b9111.87 crore. H1 <strong>EBITDA<\/strong> margin was about 28.2%. That steady climb is the core of the Dr Agarwal&#8217;s analyst review 2027.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Dr_Agarwals_Health_Care_Makes_Money\"><\/span><strong>How Dr. Agarwal&#8217;s Health Care Makes Money<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The company earns most of its revenue from eye surgeries and consultations, with smaller income from optical products and pharmacy sales inside its centres.<\/p>\n<ul>\n<li><strong>Cataract surgery:<\/strong> the largest service line. High-end lens procedures now make up about 30% of cataract volumes, lifting revenue per surgery.<\/li>\n<li><strong>Refractive and retina:<\/strong> LASIK-type procedures and retina care carry higher prices.<\/li>\n<li><strong>Optical and pharmacy:<\/strong> spectacles, lenses and medicines sold at each facility.<\/li>\n<li><strong>Network:<\/strong> 324 facilities after 39 additions in H1 FY27, through new openings and acquisitions.<\/li>\n<\/ul>\n<p>The merger with listed group company Dr. Agarwal&#8217;s Eye Hospital is now effective, which simplifies the structure. Annual revenue rose from about \u20b91,377 crore in FY24 to \u20b91,757 crore in FY25 and \u20b92,125 crore in FY26. Profit rose from \u20b995 crore to \u20b9110 crore and then \u20b9168 crore. Operating cash flow reached about \u20b9519 crore in FY26, a strong point in the Dr Agarwal&#8217;s analyst review 2027.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Growth_Triggers_in_the_Dr_Agarwals_Analyst_Review_2027\"><\/span><strong>Growth Triggers in the Dr Agarwal&#8217;s Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Network expansion:<\/strong> 21 new facilities in Q2 alone, taking the total to 324.<\/li>\n<li><strong>Premium mix:<\/strong> high-end surgeries at about 30% of cataract volumes lift average revenue.<\/li>\n<li><strong>Scale benefits:<\/strong> profit grew about 56% in Q2, faster than revenue at about 31%, as older centres mature.<\/li>\n<li><strong>Simpler structure:<\/strong> the completed merger removes the listed subsidiary.<\/li>\n<li><strong>Cash generation:<\/strong> FY26 operating cash flow of about \u20b9519 crore funds expansion, which backs the Dr Agarwal&#8217;s share price target 2027 case.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_in_the_Dr_Agarwals_Analyst_Review_2027\"><\/span><strong>Key Risks in the Dr Agarwal&#8217;s Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Rich valuation:<\/strong> a <strong>P\/E<\/strong> near 83 is well above the industry figure of about 64.<\/li>\n<li><strong>Low return on equity:<\/strong> about 8% as new centres and acquisitions take time to earn.<\/li>\n<li><strong>Expansion risk:<\/strong> adding 39 facilities in six months strains doctor hiring and margins.<\/li>\n<li><strong>Debt:<\/strong> <strong>debt to equity<\/strong> of about 0.53 includes lease liabilities on rented centres.<\/li>\n<li><strong>Foreign selling:<\/strong> FII holding fell from 58.13% to 49.56% over the year, a notable shift in the Dr Agarwal&#8217;s analyst review 2027.<\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/univest.in\/screeners\">Compare Dr Agarwal&#8217;s Health Care With Other Hospital Stocks on the Univest Screener<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Agarwals_Analyst_Review_2027_Stock_at_a_Glance\"><\/span><strong>Dr Agarwal&#8217;s Analyst Review 2027: Stock at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Share Price (17 Nov 2026 close)<\/td>\n<td>\u20b9539.95<\/td>\n<\/tr>\n<tr>\n<td>52-Week High \/ Low<\/td>\n<td>\u20b9571.90 \/ \u20b9401.00<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>\u20b917,114 crore<\/td>\n<\/tr>\n<tr>\n<td>P\/E (TTM) vs Industry<\/td>\n<td>83.3 vs 63.9<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>7.65<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share<\/td>\n<td>\u20b970.57<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>8.04%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.53<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>\u20b96.48<\/td>\n<\/tr>\n<tr>\n<td>FY26 Revenue \/ Net Profit<\/td>\n<td>\u20b92,125 crore \/ \u20b9168 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Price to <strong>book value<\/strong> of about 7.65 and return on equity near 8% show that the market pays for future growth, not current returns. In the Dr Agarwal&#8217;s analyst review 2027, the premium needs profit to keep growing near 50% a year. The <a href=\"https:\/\/univest.in\/indices\/bse-hc\/bse-healthcare-share-price-today\">BSE Healthcare<\/a> index gives a sector benchmark.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Shareholding_Trend\"><\/span><strong>Shareholding Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Holder<\/th>\n<th>Sep 2025<\/th>\n<th>Sep 2026<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Promoters<\/td>\n<td>32.42%<\/td>\n<td>32.33%<\/td>\n<td>Down 0.09 pts<\/td>\n<\/tr>\n<tr>\n<td>Foreign Investors (FII)<\/td>\n<td>58.13%<\/td>\n<td>49.56%<\/td>\n<td>Down 8.57 pts<\/td>\n<\/tr>\n<tr>\n<td>Domestic Institutions (DII)<\/td>\n<td>7.92%<\/td>\n<td>15.87%<\/td>\n<td>Up 7.95 pts<\/td>\n<\/tr>\n<tr>\n<td>Public<\/td>\n<td>1.52%<\/td>\n<td>2.24%<\/td>\n<td>Up 0.72 pts<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The Agarwal family <strong>promoter<\/strong> group holds about 32.3%. Foreign holders cut their stake by about 8.6 points. Domestic funds roughly doubled their holding to about 15.9%, absorbing that supply. The handover from foreign to domestic money is a key theme in the Dr Agarwal&#8217;s analyst review 2027.<\/p>\n<p><strong><a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_to_Watch_After_the_Dr_Agarwals_Analyst_Review_2027\"><\/span><strong>What to Watch After the Dr Agarwal&#8217;s Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>New centre ramp-up:<\/strong> how quickly the 39 facilities added in H1 reach break-even.<\/li>\n<li><strong>Margins:<\/strong> whether <strong>EBITDA<\/strong> margin holds near 28% as expansion continues.<\/li>\n<li><strong>Premium share:<\/strong> growth in high-end cataract and refractive procedures.<\/li>\n<li><strong>FII supply:<\/strong> any further stake sales by foreign holders.<\/li>\n<li><strong>Target revisions:<\/strong> a change to \u20b9620 after Q2 would reset the Dr Agarwal&#8217;s share price target 2027.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Final_Word_on_the_Dr_Agarwals_Analyst_Review_2027\"><\/span><strong>Final Word on the Dr Agarwal&#8217;s Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Dr Agarwal&#8217;s analyst review 2027<\/strong> shows record revenue, five straight quarters of profit growth and a network that keeps expanding. Motilal Oswal&#8217;s \u20b9620 target sits about 15% above the price, while the valuation already assumes strong growth.<\/p>\n<p>The <strong>Dr Agarwal&#8217;s stock outlook 2027<\/strong> depends on how fast new centres mature, whether margins hold and how foreign stake sales play out. Univest does not give a buy or sell call.<\/p>\n<div style=\"background:#FFF5F5;border-left:5px solid #C62828;padding:14px 18px;margin:24px 0;\">\n<p style=\"color:#C62828;\"><strong>Disclaimer:<\/strong> This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div class=\"faq-schema\">\n<h3><span class=\"ez-toc-section\" id=\"What_does_the_Dr_Agarwals_analyst_review_2027_show\"><\/span><strong>What does the Dr Agarwal&#8217;s analyst review 2027 show?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>It shows record revenue and steady profit growth. Q2 FY27 revenue from operations rose about 31.4% to \u20b9655 crore. Net profit rose about 56% to \u20b956.85 crore. The network grew to 324 facilities.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Dr_Agarwals_share_price_target_2027_from_brokerages\"><\/span><strong>What is the Dr Agarwal&#8217;s share price target 2027 from brokerages?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Motilal Oswal has a Buy rating with a \u20b9620 target from August 2026. The stock closed at \u20b9539.95 on 17 November 2026. That implies about 15% upside.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_Dr_Agarwals_Health_Care_perform_in_H1_FY27\"><\/span><strong>How did Dr. Agarwal&#8217;s Health Care perform in H1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>H1 FY27 revenue rose about 28.7% to \u20b91,269.48 crore. Profit rose about 50.1% to \u20b9111.87 crore. H1 EBITDA margin was about 28.2%, and 39 facilities were added in the six months.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_Dr_Agarwals_Health_Care_make_money\"><\/span><strong>How does Dr. Agarwal&#8217;s Health Care make money?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>It earns mainly from cataract, refractive and retina surgeries and consultations. Optical and pharmacy sales add smaller income. High-end cataract procedures are about 30% of volumes. FY26 revenue was about \u20b92,125 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_the_stock_expensive_based_on_the_Dr_Agarwals_analyst_review_2027\"><\/span><strong>Is the stock expensive based on the Dr Agarwal&#8217;s analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The P\/E of about 83 is above the industry figure of about 64. Price to book is about 7.65, while return on equity is about 8%. The valuation assumes profit keeps growing fast.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_does_the_Dr_Agarwals_analyst_review_2027_highlight\"><\/span><strong>What risks does the Dr Agarwal&#8217;s analyst review 2027 highlight?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The main risks are a rich valuation, low return on equity and rapid expansion. Foreign investors cut their stake from 58.13% to 49.56% over the year. Debt to equity is about 0.53, including leases.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_investors_track_after_the_Dr_Agarwals_analyst_review_2027\"><\/span><strong>What should investors track after the Dr Agarwal&#8217;s analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track how quickly the 39 new facilities from H1 reach break-even. Watch whether EBITDA margin holds near 28%. Further foreign stake sales and any change to Motilal Oswal&#8217;s \u20b9620 target also matter.<\/p>\n<\/div>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does the Dr Agarwal's analyst review 2027 show?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It shows record revenue and steady profit growth. Q2 FY27 revenue from operations rose about 31.4% to \u20b9655 crore. Net profit rose about 56% to \u20b956.85 crore. The network grew to 324 facilities.\"}},{\"@type\":\"Question\",\"name\":\"What is the Dr Agarwal's share price target 2027 from brokerages?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Motilal Oswal has a Buy rating with a \u20b9620 target from August 2026. The stock closed at \u20b9539.95 on 17 November 2026. That implies about 15% upside.\"}},{\"@type\":\"Question\",\"name\":\"How did Dr. Agarwal's Health Care perform in H1 FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"H1 FY27 revenue rose about 28.7% to \u20b91,269.48 crore. Profit rose about 50.1% to \u20b9111.87 crore. H1 EBITDA margin was about 28.2%, and 39 facilities were added in the six months.\"}},{\"@type\":\"Question\",\"name\":\"How does Dr. Agarwal's Health Care make money?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It earns mainly from cataract, refractive and retina surgeries and consultations. Optical and pharmacy sales add smaller income. High-end cataract procedures are about 30% of volumes. FY26 revenue was about \u20b92,125 crore.\"}},{\"@type\":\"Question\",\"name\":\"Is the stock expensive based on the Dr Agarwal's analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The P\/E of about 83 is above the industry figure of about 64. Price to book is about 7.65, while return on equity is about 8%. The valuation assumes profit keeps growing fast.\"}},{\"@type\":\"Question\",\"name\":\"What risks does the Dr Agarwal's analyst review 2027 highlight?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are a rich valuation, low return on equity and rapid expansion. Foreign investors cut their stake from 58.13% to 49.56% over the year. Debt to equity is about 0.53, including leases.\"}},{\"@type\":\"Question\",\"name\":\"What should investors track after the Dr Agarwal's analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Track how quickly the 39 new facilities from H1 reach break-even. Watch whether EBITDA margin holds near 28%. Further foreign stake sales and any change to Motilal Oswal's \u20b9620 target also matter.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Agarwal&#8217;s Health Care posted record Q2 FY27 revenue of \u20b9655 crore, up about 31%, and grew its network to 324 facilities, while Motilal Oswal holds a \u20b9620 target. We review results, expansion, valuation and risks for 2027.<\/p>\n","protected":false},"author":35,"featured_media":352756,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[24444,4341,11084,25650],"class_list":["post-352757","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-24444","tag-analyst-review","tag-dr-agarwals-health-care","tag-healthcare-eye-care-hospitals"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["352756"],"rank_math_title":["Dr Agarwal's Share Price Target 2027: Q2 Review"],"rank_math_description":["Dr Agarwal's analyst review 2027: record Q2 FY27 revenue of \u20b9655 crore, 324 eye care facilities, Motilal Oswal \u20b9620 target, 83x P\/E and the stock outlook."],"rank_math_focus_keyword":["Dr Agarwal's analyst review 2027"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/dr-agarwal-s-analyst-review-2027-record-revenue-and-324-centres-as-motilal-oswal.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/352757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=352757"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/352757\/revisions"}],"predecessor-version":[{"id":352758,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/352757\/revisions\/352758"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/352756"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=352757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=352757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=352757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}